ADC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Published Online First: 11 July 2007. doi:10.1136/adc.2006.103531
Archives of Disease in Childhood 2007;92:1055-1057
Copyright © 2007 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
adc.2006.103531v1
92/12/1055    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elliman, D.
Right arrow Articles by Bedford, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elliman, D.
Right arrow Articles by Bedford, H.
Related Collections
Right arrowRelated Articles

Leading articles
MMR

MMR: where are we now?

David Elliman1, Helen Bedford2

1 Islington PCT and Great Ormond Street Hospital for Children, Great Ormond Street, London, UK
2 Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, London, UK

Correspondence to:
David Elliman, Great Ormond Street Hospital for Children, Great Ormond Street, London WC1N 3JH, UK; ellimd@gosh.nhs.uk

Accepted for publication 12 June 2007

There is no scientific evidence of a link between bowel disease and/or autism and MMR vaccine. Attainment of a high uptake of the vaccine should be encouraged.

The first 150 words of the full text of this article appear below.

The combined measles, mumps and rubella (MMR) vaccine was introduced to the UK in 1988 and uptake of the vaccine rose rapidly to a high of 92%. In 1992, brands containing the Urabe strain of the mumps vaccine virus were withdrawn after it was noted to be associated with an increased risk of aseptic meningitis.1 This did not appear to have a deleterious effect on uptake. In 1995, a paper was published suggesting a link between measles vaccines and the development of bowel disorders in adulthood.2 This was associated with a small decline in the uptake of MMR vaccine. In 1998, the same group of researchers published observations of 12 children with pervasive developmental disorders and bowel disease and suggested that the latter may have led to the former.3 In eight children, the history of the onset of symptoms coincided with receipt of MMR vaccine. Although the researchers stated . . . [Full text of this article]


Related Articles

Atoms
Howard Bauchner
Arch. Dis. Child. 2007 92: 1051. [Extract] [Full Text] [PDF]

A brief digest of the December issue
Arch. Dis. Child. 2007 92: e12. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 BMJHome page
P. McIntyre and J. Leask
Improving uptake of MMR vaccine
BMJ, April 5, 2008; 336(7647): 729 - 730.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health